ArticleDiabetology & metabolic syndrome2026
GlycA-gene interactions in cardiovascular-kidney-metabolic syndrome: evidence from genetic association.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCardiovascular-Kidney-metabolic (CKM) syndrome is a concept introduced by the American Heart Association, describing systemic diseases resulting from the pathophysiological interaction among obesity, stroke, type 2 diabetes, chronic kidney disease, and cardiovascular disease. Glycoprotein acetyls (GlycA) is a novel biomarker for systemic inflammation and cardiovascular risk. This study aims to uncover the shared genetic architecture between GlycA and CKM, identify common risk loci and key tissues, and clarify the mechanisms linking these conditions.
methodsUsing summary data from large-scale GWAS studies, we evaluated both global and local genetic correlations between GlycA and various components of CKM. A cross-trait pleiotropic analysis was conducted to identify shared pleiotropic loci and related genes. FUSION was used to find susceptibility genes linked to GlycA and CKM. A comprehensive set of functional annotations and tissue-specific analyses was performed to uncover potential connections between these traits. Furthermore, a multi-trait colocalization method was utilized to explore the underlying mechanisms of the association between GlycA and CKM.
resultsOur study revealed a close genetic correlation between GlycA and CKM. We identified 260 potential SNPs that were corrected using the Bonferroni method, of which 30 passed the colocalization test (PP.H4 > 0.70). Notably, locus 9q34.2 appeared in both GlycA-T2D and GlycA-HF trait pairs. By integrating post-GWAS methods, we identified 53 potentially drug targets (CMIP, DNAJC5G, FCGRT, etc.). FUSION analysis identified 23 shared susceptibility genes for GlycA and CKM (ZPR1, IL6R, PABPC4, etc.). Analysis of tissue enrichment at the SNP level revealed pleiotropic mechanisms associated with whole blood and liver. Gene-level analysis highlighted important roles of metabolic signaling pathways. Furthermore, multi-trait colocalization analysis suggested that rs1260326 and rs2925979 may play significant roles in the mechanistic link between GlycA and CKM.
conclusionOur study confirmed a significant genetic association and shared genetic structure between GlycA and CKM, revealing potential mechanisms that may be involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.